Lifestyle Intervention With or Without Lay Volunteers to Prevent Type 2 Diabetes in People With Impaired Fasting Glucose and/or Nondiabetic Hyperglycemia: A Randomized Clinical Trial.


Journal

JAMA internal medicine
ISSN: 2168-6114
Titre abrégé: JAMA Intern Med
Pays: United States
ID NLM: 101589534

Informations de publication

Date de publication:
01 02 2021
Historique:
pubmed: 3 11 2020
medline: 18 1 2022
entrez: 2 11 2020
Statut: ppublish

Résumé

Nearly half of the older adult population has diabetes or a high-risk intermediate glycemic category, but we still lack trial evidence for effective type 2 diabetes prevention interventions in most of the current high-risk glycemic categories. To determine whether a group-based lifestyle intervention (with or without trained volunteers with type 2 diabetes) reduced the risk of progression to type 2 diabetes in populations with a high-risk glycemic category. The Norfolk Diabetes Prevention Study was a parallel, 3-arm, group-based, randomized clinical trial conducted with up to 46 months of follow-up from August 2011 to January 2019 at 135 primary care practices and 8 intervention sites in the East of England. We identified 141 973 people at increased risk of type 2 diabetes, screened 12 778 (9.0%), and randomized those with a high-risk glycemic category, which was either an elevated fasting plasma glucose level alone (≥110 and <126 mg/dL [to convert to millimoles per liter, multiply by 0.0555]) or an elevated glycated hemoglobin level (≥6.0% to <6.5%; nondiabetic hyperglycemia) with an elevated fasting plasma glucose level (≥100 to <110 mg/dL). A control arm receiving usual care (CON), a theory-based lifestyle intervention arm of 6 core and up to 15 maintenance sessions (INT), or the same intervention with support from diabetes prevention mentors, trained volunteers with type 2 diabetes (INT-DPM). Type 2 diabetes incidence between arms. In this study, 1028 participants were randomized (INT, 424 [41.2%] [166 women (39.2%)]; INT-DPM, 426 [41.4%] [147 women (34.5%)]; CON, 178 [17.3%] [70 women (%39.3)]) between January 1, 2011, and February 24, 2017. The mean (SD) age was 65.3 (10.0) years, mean (SD) body mass index 31.2 (5) (calculated as weight in kilograms divided by height in meters squared), and mean (SD) follow-up 24.7 (13.4) months. A total of 156 participants progressed to type 2 diabetes, which comprised 39 of 171 receiving CON (22.8%), 55 of 403 receiving INT (13.7%), and 62 of 414 receiving INT-DPM (15.0%). There was no significant difference between the intervention arms in the primary outcome (odds ratio [OR], 1.14; 95% CI, 0.77-1.7; P = .51), but each intervention arm had significantly lower odds of type 2 diabetes (INT: OR, 0.54; 95% CI, 0.34-0.85; P = .01; INT-DPM: OR, 0.61; 95% CI, 0.39-0.96; P = .033; combined: OR, 0.57; 95% CI, 0.38-0.87; P = .01). The effect size was similar in all glycemic, age, and social deprivation groups, and intervention costs per participant were low at $153 (£122). The Norfolk Diabetes Prevention lifestyle intervention reduced the risk of type 2 diabetes in current high-risk glycemic categories. Enhancing the intervention with DPM did not further reduce diabetes risk. These translatable results are relevant for current diabetes prevention efforts. ISRCTN Registry Identifier: ISRCTN34805606.

Identifiants

pubmed: 33136119
pii: 2772239
doi: 10.1001/jamainternmed.2020.5938
pmc: PMC7607494
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

168-178

Subventions

Organisme : Department of Health
ID : PB-PG-0609-19144
Pays : United Kingdom
Organisme : Department of Health
ID : PDA/02/06/031
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Auteurs

Michael Sampson (M)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.
Norwich Medical School, University of East Anglia, Norwich, England.

Allan Clark (A)

Norwich Medical School, University of East Anglia, Norwich, England.

Max Bachmann (M)

Norwich Medical School, University of East Anglia, Norwich, England.

Nikki Garner (N)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.

Lisa Irvine (L)

Norwich Medical School, University of East Anglia, Norwich, England.

Amanda Howe (A)

Norwich Medical School, University of East Anglia, Norwich, England.

Colin Greaves (C)

School of Sport, Exercise & Rehabilitation Sciences, University of Birmingham, Birmingham, England.
University of Exeter Medical School, College of Medicine & Health, University of Exeter, Exeter, England.

Sara Auckland (S)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.

Jane Smith (J)

Norwich Medical School, University of East Anglia, Norwich, England.
University of Exeter Medical School, College of Medicine & Health, University of Exeter, Exeter, England.

Jeremy Turner (J)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.

Dave Rea (D)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.

Gerry Rayman (G)

Department of Diabetes and Endocrinology, Ipswich General Hospital, Ipswich, England.

Ketan Dhatariya (K)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.

W Garry John (WG)

Department Clinical Biochemistry, Norfolk and Norwich University Hospital NHS Trust, Norwich, England.

Garry Barton (G)

Norwich Medical School, University of East Anglia, Norwich, England.

Rebecca Usher (R)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.

Clare Ferns (C)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.

Melanie Pascale (M)

Elsie Bertram Diabetes Centre, Department of Diabetes and Endocrinology, Norfolk and Norwich University Hospital National Health Service Trust, Norwich, England.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH